Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender WomenLinda‐Gail Bekker, Flavia Matovu Kiweewa, Moupali Das et al.|New England Journal of Medicine|2024Cited by 471
Analysis of the HIV Vaccine Trials Network 702 Phase 2b–3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition RiskZoe Moodie, M. Juliana McElrath, Yunda Huang et al.|The Journal of Infectious Diseases|2022Cited by 50